161 related articles for article (PubMed ID: 22974428)
1. Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.
Tanaka N; Asakawa I; Fujimoto K; Anai S; Hirayama A; Hasegawa M; Konishi N; Hirao Y
BMC Urol; 2012 Sep; 12():28. PubMed ID: 22974428
[TBL] [Abstract][Full Text] [Related]
2. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
[TBL] [Abstract][Full Text] [Related]
3.
Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs.
Slade AN; Dahman B; Chang MG
Brachytherapy; 2020; 19(1):6-12. PubMed ID: 31611160
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
9. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
10. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662
[TBL] [Abstract][Full Text] [Related]
11. Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer.
Åström L; Sandin F; Holmberg L
Radiother Oncol; 2018 Dec; 129(3):561-566. PubMed ID: 30193693
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
Stock RG; Stone NN; Cesaretti JA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
[TBL] [Abstract][Full Text] [Related]
13. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer.
Kanai K; Nakashima J; Sugawara A; Shigematsu N; Nagata H; Kikuchi E; Miyajima A; Nakagawa K; Kubo A; Oya M
Int J Clin Oncol; 2009 Dec; 14(6):502-6. PubMed ID: 19967485
[TBL] [Abstract][Full Text] [Related]
14. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation.
McGrath SD; Antonucci JV; Fitch DL; Ghilezan M; Gustafson GS; Vicini FA; Martinez AA; Kestin LL
Brachytherapy; 2010; 9(2):137-44. PubMed ID: 19850537
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy.
Patel N; Souhami L; Mansure JJ; Duclos M; Aprikian A; Faria S; David M; Cury FL
Brachytherapy; 2014; 13(5):450-5. PubMed ID: 25023396
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
[TBL] [Abstract][Full Text] [Related]
17. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator.
Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.
Lo AC; Morris WJ; Lapointe V; Hamm J; Keyes M; Pickles T; McKenzie M; Spadinger I
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):87-93. PubMed ID: 24331654
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients.
Leduc N; Atallah V; Creoff M; Rabia N; Taouil T; Escarmant P; Vinh-Hung V
Brachytherapy; 2015; 14(6):826-33. PubMed ID: 26489920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
